Key Points:
It is necessary to include future non-breast cancer costs in cost-effectiveness analyses.

Inclusion of future non-breast cancer costs does not change our conclusions about the optimal treatment strategy in Iran.,
Institute for Medical Technology Assessment (iMTA)

Ansaripour, A., Uyl-de Groot, C., & Redekop, K. (2018). Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’. PharmacoEconomics, 1–2. doi:10.1007/s40273-018-0620-y